

ASX Release

NEWSLETTER MARCH 2021

PERTH, AUSTRALIA – 29 Mar 2021: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, has published a newsletter for shareholders.

A copy of the newsletter is available via SUDA's website:

<https://sudapharma.com/investors/media/>

SUDA's CEO and MD, Dr. Michael Baker, said: "We are looking forward to a positive 2021 as we forge ahead with our current portfolio of products in addition to looking to bolster the pipeline. We are expecting a busy year and we are excited to bring our shareholders additional updates throughout the course of 2021."

For and on behalf of the Board and for further information please contact:

Dr Michael Baker

Chief Executive Officer & Managing Director

SUDA Pharmaceuticals Ltd

Tel +61 (0) 403 468 187

mbaker@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem tartrate for the treatment of short-term insomnia. ZolpiMist is approved by the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of migraine headache, motion sickness, drug resistant epilepsy and certain cancers.

For more information, visit www.sudapharma.com